Evidence map›Paper›PMID 34917255›Full record

ArticleACS medicinal chemistry letters2021

17β-Hydroxysteroid Dehydrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer.

Emanuele M Gargano, Abdelrahman Mohamed, Ahmed S Abdelsamie, Giuseppe F Mangiatordi, Hanna Drzewiecka, Paweł P Jagodziński, Arcangela Mazzini, Chris J van Koppen, Matthias W Laschke, Orazio Nicolotti and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Emanuele M GarganoDepartment of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C23, D-66123 Saarbrücken, Germany.
Abdelrahman MohamedDepartment of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C23, D-66123 Saarbrücken, Germany.
Ahmed S AbdelsamieDepartment of Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus E81, D-66123 Saarbrücken, Germany.
Giuseppe F MangiatordiDipartimento di Farmacia Scienze del Farmaco, Università degli Studi di Bari, V. Orabona 4, I-70125 Bari, Italy.ORCID https://orcid.org/0000-0003-4042-2841
Hanna DrzewieckaDepartment of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Świȩcickiego 6 Street, 60-781 Poznan, Poland.
Paweł P JagodzińskiDepartment of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Świȩcickiego 6 Street, 60-781 Poznan, Poland.
Arcangela MazziniDepartment of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C23, D-66123 Saarbrücken, Germany.
Chris J van KoppenElexoPharm GmbH, Campus A12, D-66123 Saarbrücken, Germany.ORCID https://orcid.org/0000-0003-2799-6728
Matthias W LaschkeInstitute for Clinical and Experimental Surgery, Saarland University, D-66421, Homburg, Saar, Germany.
Orazio NicolottiDipartimento di Farmacia Scienze del Farmaco, Università degli Studi di Bari, V. Orabona 4, I-70125 Bari, Italy.ORCID https://orcid.org/0000-0001-6533-5539
Angelo CarottiDipartimento di Farmacia Scienze del Farmaco, Università degli Studi di Bari, V. Orabona 4, I-70125 Bari, Italy.
Sandrine Marchais-OberwinklerDepartment of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C23, D-66123 Saarbrücken, Germany.
Rolf W HartmannDepartment of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C23, D-66123 Saarbrücken, Germany.ORCID https://orcid.org/0000-0002-5871-5231
Martin FrotscherDepartment of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C23, D-66123 Saarbrücken, Germany.ORCID https://orcid.org/0000-0003-1777-8890

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the face of the clinical challenge posed by non-small cell lung cancer (NSCLC), the present need for new therapeutic approaches is genuine. Up to now, no proof existed that 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) is a viable target for treating this disease. Synthesis of a rationally designed library of 2,5-disubstituted furan derivatives followed by biological screening led to the discovery of 17β-HSD1 inhibitor

Identifiers

PMID34917255
PMCPMC8667298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.